

Primary Biliary Cholangitis (Cirrhosis) pipeline Research Monitor, 2020- Drugs, Companies, Clinical Trials, R&D pipeline updates, status and outlook

<https://marketpublishers.com/r/P61F6569BC61EN.html>

Date: July 2020

Pages: 102

Price: US\$ 1,599.00 (Single User License)

ID: P61F6569BC61EN

Abstracts

2020 Primary Biliary Cholangitis (Cirrhosis) PIPELINE HIGHLIGHTS

Primary Biliary Cholangitis (Cirrhosis) is one of the widely researched conditions during 2020 with 20 companies actively focusing on realizing pipeline's potential.

Development of Primary Biliary Cholangitis (Cirrhosis) medicines is identified as integral to the strategy of the majority of companies operating in the industry.

Global Primary Biliary Cholangitis (Cirrhosis) market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates. Increasing number of companies are assessing the feasibility of developing treatment options for Primary Biliary Cholangitis (Cirrhosis).

Good progress is anticipated during 2020 and 2021 with Primary Biliary Cholangitis (Cirrhosis) pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials. Primary Biliary Cholangitis (Cirrhosis) pipeline continues to expand and progress with novel mechanisms and diverse routes of administration being tested by companies.

Primary Biliary Cholangitis (Cirrhosis) DRUG DEVELOPMENT PIPELINE OVERVIEW

The "Primary Biliary Cholangitis (Cirrhosis) pipeline Research Monitor, 2020" report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.

This Primary Biliary Cholangitis (Cirrhosis) pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.

The competitive intelligence report on Primary Biliary Cholangitis (Cirrhosis) presents detailed insights into therapeutic drug pipeline development, industry news, deals, and

analysis across the length and breadth of the Primary Biliary Cholangitis (Cirrhosis) pipeline. Information on R&D pipeline updates, results of key clinical trials are also included in the report.

Primary Biliary Cholangitis (Cirrhosis) DRUG PROFILES

Primary Biliary Cholangitis (Cirrhosis) development pipeline including projects in early- and late-stage development are detailed in the report. Details of clinical trial data and submissions to regulatory authorities are also provided. For the drug candidates included in the report, the following information is provided-

Current Status of Development including phase advancements, regulatory approvals of phases, acquisitions, licensing and technology transfers, product launches in various markets, and others.

Phase of development

Mechanism of Action

Route of Administration

Companies involved including originator, licensing companies, developer, investors, and others

New molecular entity details

Orphan drug designation and other special status provided by regulators

Primary Biliary Cholangitis (Cirrhosis) COMPANY PROFILES

Both small size and large size pharmaceutical companies are investing their resources in Primary Biliary Cholangitis (Cirrhosis) drug development operations. Further, financial institutions are extending support to small pharmaceutical companies, universities, and other researchers for the development of treatment of Primary Biliary Cholangitis (Cirrhosis). Partnerships and acquisitions are also increasingly observed in the pipeline.

This research report presents an analysis of 20 Primary Biliary Cholangitis (Cirrhosis) companies including company overview, key snapshot, contact information, and their strategies on accelerating Primary Biliary Cholangitis (Cirrhosis) pipeline development. Mid-stage and early portfolios of these companies are analyzed in detail in the report.

Companies analyzed in the report include- Abcuro Inc, Allergan Plc, Cadila Healthcare Ltd, Calliditas Therapeutics AB, Chia Tai Tianqing Pharmaceutical Group Co Ltd., Dr. Falk Pharma GmbH, Eli Lilly and Co, Enanta Pharmaceuticals Inc, Genfit, GenKyoTex SA, Gilead Sciences Inc, GlaxoSmithKline Plc, Kowa Co Ltd, MYR Pharma, NGM Biopharmaceuticals Inc, Novartis AG, PRISM Pharma Co Ltd, Suzhou Zelgen Biopharmaceutical Co Ltd, Tiziana Life Sciences, Virobay Inc

REASONS TO BUY

The current market conditions are forcing companies and investors worldwide to prioritize their investments and accelerate pipeline candidates only through careful quantitative assessment.

This research work assists decision makers in pharmaceutical companies towards successful pipeline development through critically evaluated pipeline data

Buyers can identify most promising drug candidates for treatment of Primary Biliary Cholangitis (Cirrhosis)

It allows users to strengthen their pipeline through acquisitions, licensing and collaborations

Users can estimate possible delays in the delivery of pipeline or launch of new products

Stay ahead of competition through understanding their pipeline progression, strategies and outlook

The report details all the pipeline candidates under investigation in various stages of development from Phase I through to Phase III to enable business development managers to understand the impact of new launches.

Optimize your licensing and technology transfer strategies through identification of prospect partners

Contents

1. INTRODUCTION TO PRIMARY BILIARY CHOLANGITIS (CIRRHOSIS)

- 1.1 Primary Biliary Cholangitis (Cirrhosis)- Disease overview
- 1.2 Primary Biliary Cholangitis (Cirrhosis)- Market Size
- 1.3 Primary Biliary Cholangitis (Cirrhosis)- Companies Involved

2. PRIMARY BILIARY CHOLANGITIS (CIRRHOSIS) PIPELINE SNAPSHOT- 2020

- 2.1 Primary Biliary Cholangitis (Cirrhosis) Pipeline by Phase
- 2.2 Primary Biliary Cholangitis (Cirrhosis) Pipeline by Mechanism of Action
- 2.3 Primary Biliary Cholangitis (Cirrhosis) Pipeline by Route of Administration
- 2.4 Primary Biliary Cholangitis (Cirrhosis) Pipeline- New Molecular Entities
- 2.5 Primary Biliary Cholangitis (Cirrhosis) Pipeline- Orphan Drug Designation/ Special Designation

3. PRIMARY BILIARY CHOLANGITIS (CIRRHOSIS) DRUG PROFILES

- 3.1 Current Status
- 3.2 Primary Biliary Cholangitis (Cirrhosis) Drug Snapshot
- 3.3 Primary Biliary Cholangitis (Cirrhosis) Therapeutic Candidates- Originator/Licensor
- 3.4 Route of Administration
- 3.5 Mechanism of Action
- 3.6 NME
- 4.1 Abcuro Inc Primary Biliary Cholangitis (Cirrhosis) Pipeline Insights and Clinical Trials
- 4.2 Allergan Plc Primary Biliary Cholangitis (Cirrhosis) Pipeline Insights and Clinical Trials
- 4.3 Cadila Healthcare Ltd Primary Biliary Cholangitis (Cirrhosis) Pipeline Insights and Clinical Trials
- 4.4 Calliditas Therapeutics AB Primary Biliary Cholangitis (Cirrhosis) Pipeline Insights and Clinical Trials
- 4.5 Chia Tai Tianqing Pharmaceutical Group Co Ltd. Primary Biliary Cholangitis (Cirrhosis) Pipeline Insights and Clinical Trials
- 4.6 Dr. Falk Pharma GmbH Primary Biliary Cholangitis (Cirrhosis) Pipeline Insights and Clinical Trials
- 4.7 Eli Lilly and Co Primary Biliary Cholangitis (Cirrhosis) Pipeline Insights and Clinical Trials

- 4.8 Enanta Pharmaceuticals Inc Primary Biliary Cholangitis (Cirrhosis) Pipeline Insights and Clinical Trials
- 4.9 Genfit Primary Biliary Cholangitis (Cirrhosis) Pipeline Insights and Clinical Trials
- 4.10 GenKyoTex SA Primary Biliary Cholangitis (Cirrhosis) Pipeline Insights and Clinical Trials
- 4.11 Gilead Sciences Inc Primary Biliary Cholangitis (Cirrhosis) Pipeline Insights and Clinical Trials
- 4.12 GlaxoSmithKline Plc Primary Biliary Cholangitis (Cirrhosis) Pipeline Insights and Clinical Trials
- 4.13 Kowa Co Ltd Primary Biliary Cholangitis (Cirrhosis) Pipeline Insights and Clinical Trials
- 4.14 MYR Pharma Primary Biliary Cholangitis (Cirrhosis) Pipeline Insights and Clinical Trials
- 4.15 NGM Biopharmaceuticals Inc Primary Biliary Cholangitis (Cirrhosis) Pipeline Insights and Clinical Trials
- 4.16 Novartis AG Primary Biliary Cholangitis (Cirrhosis) Pipeline Insights and Clinical Trials
- 4.17 PRISM Pharma Co Ltd Primary Biliary Cholangitis (Cirrhosis) Pipeline Insights and Clinical Trials
- 4.18 Suzhou Zelgen Biopharmaceutical Co Ltd Primary Biliary Cholangitis (Cirrhosis) Pipeline Insights and Clinical Trials
- 4.19 Tiziana Life Sciences Primary Biliary Cholangitis (Cirrhosis) Pipeline Insights and Clinical Trials
- 4.20 Virobay Inc Primary Biliary Cholangitis (Cirrhosis) Pipeline Insights and Clinical Trials

5. PRIMARY BILIARY CHOLANGITIS (CIRRHOSIS) MARKET NEWS AND UPDATES

6. APPENDIX

- 6.1 Sources and Methodology
- 6.2 Contact Information

I would like to order

Product name: Primary Biliary Cholangitis (Cirrhosis) pipeline Research Monitor, 2020- Drugs, Companies, Clinical Trials, R&D pipeline updates, status and outlook

Product link: <https://marketpublishers.com/r/P61F6569BC61EN.html>

Price: US\$ 1,599.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P61F6569BC61EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

